Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Clever Culture Systems Ltd

Company price
0.014 AUD -0.00 ( 12.50%)
Last update at 2026-11-12T04:14:00Z
VOLUME
3899115
Market Cap
37.10M

Momentum Score

…

Clever Culture Systems Limited engages in the research, development, and commercialization of technology solutions for the medical industry in Australia, the United States, United Kingdom, Germany, Denmark, Australia, Netherlands, Sweden, China, and France. The company offers Automated Plate Assessment System, a solution that automates the imaging, analysis, and interpretation of microbiology culture plates primarily for microbiology laboratories and pharmaceutical manufacturing sector; Digital Microbiology; and APAS modules, an artificial intelligence algorithm that works with the APAS Independence to enable digital microbiology culture plate reading. It also develops APAS intelligent imaging technology for various applications, which includes urine screening, infection control testing, and antimicrobial susceptibility testing. The company serves global pharmaceutical manufacturers, clinical laboratories, and microbiology labs. The company was formerly known as LBT Innovations Limited and changed its name to Clever Culture Systems Limited in November 2024. Clever Culture Systems Limited was incorporated in 2004 and is headquartered in Adelaide, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.01
Low
0.03
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Clever Culture Systems Ltd is an ASX-listed company that appears to operate in automated microbiology and diagnostic culture technologies, though public disclosures are limited. Long-term growth may be driven by adoption of laboratory automation, recurring consumables revenue and successful regulatory clearances and commercial partnerships. Investors may find exposure to lab automation attractive if the company achieves product validation and market traction.

Material risks include limited public information and small-cap liquidity, execution and regulatory approval risk typical of diagnostic-device companies, dependence on commercialisation success and the need for additional funding.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.02
Dividend Yield
-
Revenue TTM
4.62M
Revenue Per Share
0.00
Gross Profit TTM
3.40M
Debt / Equity
0.40
ROE
-33.99%
Net Debt
1.29M
ROCE
-46.00%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -4.71M -0.09M -4.67M -20.88M -8.76M
Net income -2.24M 1.68M -3.74M -22.52M -6.64M
Selling general administrative - 3.56M 4.24M 4.62M 5.19M
Selling and marketing expenses - 0.33M 0.13M 0.09M 0.28M
Gross profit -1.98M 3.96M 1.11M 1.71M 1.33M
Reconciled depreciation - 0.23M 0.24M 3.30M 2.93M
Ebit -4.41M -0.01M -4.29M -20.41M -8.65M
Ebitda -3.73M 0.22M -4.05M -17.12M -5.72M
Depreciation and amortization 0.68M 0.23M 0.24M 3.30M 2.93M
Operating income -4.41M -1.17M -4.74M -7.04M -7.90M
Other operating expenses 9.02M 6.63M 6.00M 9.17M 10.03M
Interest expense 0.19M 0.08M 0.39M 0.47M 0.10M
Tax provision - -1.77M -0.94M 1.64M -2.12M
Interest income - 0.06M 0.05M 0.02M -
Net interest income - -0.02M -0.33M -0.45M -0.10M
Income tax expense -2.48M -1.77M -0.94M 1.64M -2.12M
Total revenue 4.62M 5.46M 1.26M 2.13M 2.13M
Total operating expenses 2.43M 5.14M 5.85M 8.74M 9.23M
Cost of revenue 6.59M 1.50M 0.15M 0.43M 0.80M
Total other income expense net -0.31M 1.09M 0.07M -13.85M -0.86M
Net income from continuing ops - 1.68M -3.74M -22.52M -6.64M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 13.55M 10.77M 7.93M 7.37M 31.52M
Intangible assets 2.49M 2.45M - - 16.15M
Other current assets - 1.08M 1.00M 0.85M 1.21M
Total liab 6.02M 5.12M 5.51M 7.47M 10.19M
Total stockholder equity 7.52M 5.64M 2.42M -0.10M 21.34M
Other current liab 1.20M 1.07M 0.88M 2.02M 0.85M
Common stock 57.55M 54.16M 53.11M 47.02M 46.27M
Capital stock - 54.16M 53.11M 47.02M 46.27M
Retained earnings -52.14M -50.19M -52.77M -49.07M -26.59M
Cash 1.70M 1.26M 2.35M 2.02M 2.79M
Total current liabilities 3.97M 2.35M 1.53M 4.19M 2.86M
Current deferred revenue 0.56M 0.29M - 0.29M 0.03M
Net debt 1.29M 0.95M 0.85M 1.37M 1.50M
Short term debt 1.82M 0.40M 0.21M 1.19M 1.16M
Short long term debt - 0.18M - 0.99M 0.96M
Short long term debt total 2.98M 2.21M 3.19M 3.39M 4.29M
Total current assets 6.40M 5.26M 5.52M 4.84M 6.98M
Net receivables 2.79M 1.49M 0.56M 0.48M 2.00M
Long term debt - 0.80M 1.74M 0.76M 1.50M
Inventory 1.91M 1.43M 1.62M 1.49M 0.98M
Accounts payable 0.40M 0.59M 0.44M 0.68M 0.82M
Accumulated other comprehensive income 2.12M 1.67M 2.09M 1.95M 1.65M
Non currrent assets other - 0.23M - - -
Non current assets total 7.14M 5.51M 2.41M 2.53M 24.55M
Capital lease obligations - 1.24M 1.45M 1.64M 1.82M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - - -0.01M -0.30M -1.24M
Total cashflows from investing activities -0.47M -2.33M - -0.30M -
Net borrowings - -0.77M - -0.72M -0.47M
Total cash from financing activities 3.48M 0.08M 4.01M 0.94M -0.64M
Net income -2.24M 1.68M -3.74M -22.52M -6.64M
Change in cash 0.43M -1.08M 0.33M -0.77M -6.83M
Begin period cash flow 1.26M 2.35M 2.02M 2.79M 9.62M
End period cash flow 1.70M 1.26M 2.35M 2.02M 2.79M
Total cash from operating activities -2.57M - - - -
Issuance of capital stock - 1.06M 6.12M 2.00M -
Depreciation 0.68M - - - -
Other cashflows from investing activities - -2.30M - -0.30M -
Change to inventory -0.49M - - - -
Change to account receivables -0.46M - - - -
Sale purchase of stock - -0.00M -0.54M -0.17M -
Other cashflows from financing activities -0.29M -0.21M - -0.18M -
Capital expenditures 0.01M 2.33M 0.01M 0.60M 1.24M
Change in working capital -1.96M - - - -
Other non cash items 0.94M - - - -
Free cash flow -2.58M -1.17M -3.68M -2.00M -6.19M

Peer Comparison*

Sector: Technology Industry: Software - Infrastructure

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CC5
Clever Culture Systems Ltd
-0.00
12.50%
0.01 - - 8.03 4.93 8.31 308.03
XYZ
Block, Inc
-0.24
0.19%
125.71 111.51 15.77 2.89 2.22 1.63 11.60
MP1
Megaport Ltd
-0.52
2.70%
18.74 - 138.89 13.81 4.10 12.09 155.41
CCL
Cuscal Ltd
-0.15
2.52%
5.80 26.77 20.28 1.97 2.73 5.15 10.93
AXQ
Aura Consolidated Group, Inc.
-0.69
18.35%
3.07 - - 3.78 - 5.49 -

Profile*

Clever Culture Systems Ltd

Clever Culture Systems Limited engages in the research, development, and commercialization of technology solutions for the medical industry in Australia, the United States, United Kingdom, Germany, Denmark, Australia, Netherlands, Sweden, China, and France. The company offers Automated Plate Assessment System, a solution that automates the imaging, analysis, and interpretation of microbiology culture plates primarily for microbiology laboratories and pharmaceutical manufacturing sector; Digital Microbiology; and APAS modules, an artificial intelligence algorithm that works with the APAS Independence to enable digital microbiology culture plate reading. It also develops APAS intelligent imaging technology for various applications, which includes urine screening, infection control testing, and antimicrobial susceptibility testing. The company serves global pharmaceutical manufacturers, clinical laboratories, and microbiology labs. The company was formerly known as LBT Innovations Limited and changed its name to Clever Culture Systems Limited in November 2024. Clever Culture Systems Limited was incorporated in 2004 and is headquartered in Adelaide, Australia.

16 Anster Street, Adelaide, SA, Australia, 5000

61 8 8227 1555

Name Title Year Born
Mr. Brenton John Barnes CEO, MD & Director NA
Mr. Raymond Robert Ridge B.A., BA (Acc), C.A., GIA (cert) CFO & Company Secretary NA
Dr. Steven Giglio Chief Scientific Officer NA
Mr. Rhys Hill Chief Technology Officer - APAS Inventor NA
Mr. Jack Brown Chief Revenue Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…